IJE Advance Access originally published online on May 27, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
International Journal of Epidemiology, Volume 33, Number 3, pp. 445-453
IJE vol.33 no.3 © International Epidemiological Association 2004; all rights reserved.
Reprints and Reflections |
Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence1,,2
,3
* The Channing Laboratory, Department of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts;
Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts; and
Technology Assessment Group, Department of Health Policy and Management, Harvard School of Public Health, Boston, Massachusetts
Accepted 19 July 1990
Received 21 May 1990
| The first 150 words of the full text of this article appear below. |
Considerable epidemiological evidence has accumulated regarding the effect of post-menopausal estrogens on coronary heart disease risk. Five hospital-based case-control studies yielded inconsistent but generally null results; however, these are difficult to interpret due to the problems in selecting appropriate controls. Six population-based case-control studies found decreased relative risks among estrogen users, though only 1 was statistically significant. Three cross-sectional studies of women with or without stenosis on coronary angiography each showed markedly less atherosclerosis among estrogen users. Of 16 prospective studies, 15 found decreased relative risks, in most instances, statistically significant. The Framingham study alone observed an elevated risk, which was not statistically significant when angina was omitted. A reanalysis of the data showed a nonsignificant protective effect among younger women and a nonsignificant increase in risk among older women. Overall, the bulk of the evidence strongly supports a protective effect of estrogens that is unlikely to be explained by
| Introduction |
|---|
| Methods for quantitative overview |
|---|
| Hospital-based case-control studies |
|---|
| Population-based case-control studies |
|---|
| Cross-sectional studies |
|---|
| Prospective studies |
|---|
| Results of the quantitative overview |
|---|
| Discussion |
|---|
| Conclusion |
|---|
This article has been cited by other articles:
![]() |
R. L. Prentice, R. Langer, M. L. Stefanick, B. V. Howard, M. Pettinger, G. Anderson, D. Barad, J. D. Curb, J. Kotchen, L. Kuller, et al. Combined Postmenopausal Hormone Therapy and Cardiovascular Disease: Toward Resolving the Discrepancy between Observational Studies and the Women's Health Initiative Clinical Trial Am. J. Epidemiol., September 1, 2005; 162(5): 404 - 414. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Saracci, J. Olsen, and A. Hofman Health research policy in the European Union BMJ, June 25, 2005; 330(7506): 1459 - 1460. [Full Text] [PDF] |
||||
![]() |
G. D. Smith Classics in epidemiology: should they get it right? Int. J. Epidemiol., June 1, 2004; 33(3): 441 - 442. [Full Text] [PDF] |
||||


